Tibor Soós, PhD
founder
As an early-stage company formed by a team of organic chemists and biochemists we want to provide medicinal chemists with an alternative to irreversible covalent warheads and drug developers with new patentable preclinical candidates.
The Hungarian Intellectual Property Office issues our first national patent for c-Jun N-terminal kinase (JNK) inhibitors
We filed the European patent based on the preliminary positive evaluation issued by the EPO earlier